Arca
Skip to content
Tools
Tools

Protein kinase C (PKC)

Family in Homo sapiens that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 1
  • In phases 1 to 3: 4
  • Sponsors: 3
  • Genes: 11

Who is on it, and how far along

Every drug ChEMBL records acting on PRKCA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5

Approved1

  • Midostaurin

Phase 30

    Phase 22

    • Sotrastaurin
    • UCN-01

    Phase 12

    • CEP-2563
    • GSK-690693

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • ReBio Pharma120%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Protein kinase C (PKC) inhibitor.
    MidostaurinApprovedNovartis PharmaceuticalsSmall moleculeInhibitor16
    SotrastaurinPhase 2ReBio PharmaSmall moleculeInhibitor1
    UCN-01Phase 2—Small moleculeInhibitor0
    CEP-2563Phase 1—Small moleculeInhibitor0
    GSK-690693Phase 1GSKSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
    Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)MidostaurinPhase 3Not yet recruitingUniversity Hospital, ToulouseNov 19, 2026
    Study of Neoadjuvant RBP-01 In Patients With Primary Uveal MelanomaSotrastaurinPhase 1 / Phase 2Not yet recruitingReBio PharmaAug 5, 2026
    Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid LeukemiaMidostaurinPhase 1 / Phase 2Not yet recruitingUniversity Hospital, BordeauxJul 24, 2026
    Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AMLMidostaurin—Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMay 7, 2026
    FLT3-ITD Targeted Therapy in Fit AML PatientsMidostaurinPhase 2 / Phase 3Not yet recruitingEuropean Organisation for Research and Treatment of Cancer - EORTCFeb 23, 2026
    Revumenib in Combination With 7+3 + Midostaurin in AMLMidostaurinPhase 1RecruitingRichard Stone, MDMar 15, 2024
    Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia PatientsMidostaurinPhase 1RecruitingUniversity Hospital TuebingenFeb 9, 2024
    Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)Midostaurin—RecruitingAcute Leukemia French AssociationMar 2, 2021
    Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)MidostaurinPhase 1 / Phase 2RecruitingTechnische Universität DresdenMay 12, 2020

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2093867, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.